An Israeli NeuroQuest biotech firm has launched clinical trials on its blood-based biomarker test to detect Alzheimer’s disease.
NeuroQuest announced last month they had entered into a service agreement with the University of California, San Diego for collection and processing of 700 blood samples for the U.S. clinical validation trials.
Read more: jewishpress.com
